{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-055449","form_type":"8-K/A","ticker":"PURR","cik":"0002078856","company_name":"Hyperliquid Strategies Inc","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.197459+00:00","generated_at":"2026-05-16T02:12:00.482753+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"confidence":"medium","headline":"Hyperliquid Strategies files audited Sonnet FY2025 financials after combo","bullets":["Sonnet's audited financials for FY ended Sep 30, 2025 filed; pro forma data included.","Market value of Sonnet common equity held by non-affiliates: $4.15M as of Mar 31, 2025 ($1.34/share).","Sonnet is a clinical-stage oncology biotech with FHAB platform; lead SON-1010 in solid tumors.","Business combination closed Dec 2, 2025; Hyperliquid now wholly owns Sonnet.","Sonnet has history of operating losses and requires significant additional capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-055449","json":"https://secwatch.observer/filing/0001193125-26-055449.json","markdown":"https://secwatch.observer/filing/0001193125-26-055449.md","text":"https://secwatch.observer/filing/0001193125-26-055449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2078856/000119312526055449/0001193125-26-055449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2078856/000119312526055449/purr-20251202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:12:00.482753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}